SCHEMBL3678451

SCHEMBL3678451

CC(=O)OC1C=CCCCC1

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.33
NPC1 O15118 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CA12 O43570 4/20 0.33
CA9 Q16790 4/20 0.33
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CHRM2 P08172 5/20 0.32
CHRM1 P11229 3/20 0.32
CHRM4 P08173 2/20 0.32
CHRM3 P20309 2/20 0.32
SLC18A3 Q16572 1/20 0.31
CYP2D6 P10635 1/20 0.31
EPHX1 P07099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3674322 0.98 CA12 (0.34) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL15750117 0.98 CA12 (0.34) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL9013512 0.98 CA12 (0.34) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL3674320 0.98 CA12 (0.34) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL9013516 0.98 CA12 (0.34) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL12054453 0.98 CA12 (0.34) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL1571430 0.94 MAPT (0.34) MAPTMEN1KMT2ACA12CA9
SCHEMBL17777177 0.94 MAPT (0.34) MAPTMEN1KMT2ACA12CA9
SCHEMBL9247730 0.94 MAPT (0.34) MAPTMEN1KMT2ACA12CA9
SCHEMBL3675433 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713320-A2 BCAT2 INHIBITORS Agios Pharmaceuticals, Inc. (US) 2026-03-25 EP disclosed
WO-2024238820-A2 BCAT2 INHIBITORS AGIOS PHARMACEUTICALS, INC. (US) 2024-11-21 WO disclosed
EP-4430036-A2 BCAT2 INHIBITORS Agios Pharmaceuticals, Inc. (US) 2024-09-18 EP disclosed
WO-2023086539-A2 BCAT2 INHIBITORS AGIOS PHARMACEUTICALS, INC. (US) 2023-05-19 WO disclosed
US-7723423-B2 Gas-barrier resin composition CRYOVAC, INC. (US) 2010-05-25 US disclosed
EP-1746131-B1 Gas-barrier resin composition CRYOVAC INC (US) 2009-01-21 EP disclosed
US-7285598-B2 Polymer and process for producing the same KURARAY CO., LTD. (JP) 2007-10-23 US disclosed
US-20070093599-A1 Gas-barrier resin composition CRYOVAC, INC. (US) 2007-04-26 US disclosed
US-20070021556-A1 Gas-barrier resin composition KURARAY CO. LTD. (JP) 2007-01-25 US disclosed
EP-1746131-A2 Gas-barrier resin composition Cryovac, Inc. (US) 2007-01-24 EP disclosed
US-20060149009-A1 Produced by ring-opening, in the presence of a metal alkylidene complex comprising a ligand with an imidazolidine structure, a cyclic olefin comprising at least one cyclic olefin further comprising a hydroxy group or a functional group that can be converted into a hydroxy group, and hydrogenating KURARAY CO., LTD. (JP) 2006-07-06 US disclosed
EP-1598384-A1 NOVEL POLYMER AND PROCESS FOR PRODUCING THE SAME KURARAY CO., LTD. (JP) 2005-11-23 EP disclosed
CN-1071736-C A process for the preparation of carboxylic esters derived from allylic alcohols FIRMENICH & CIE (CH) 2001-09-26 CN disclosed
WO-1998030535-A1 AMINO ACID COMPOUNDS COCKBAIN JULIAN (GB) 1998-07-16 WO disclosed
CN-1113226-A A process for the preparation of carboxylic esters derived from allylic alcohols FIRMENICH & CIE (CH) 1995-12-13 CN disclosed